Currently, there are 36.96M common shares owned by the public and among those 34.99M shares have been available to trade.
Insiders at the company have transacted a total of 47 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 28 of these insider trades were purchases, accounting for 218,675 shares. Insider sales of the common stock occurred on 19 occasions, with total insider shares sold totaling 10,177,550 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 29.80, up 1.04%. The company’s stock has a 5-day price change of 4.65% and -3.56% over the past three months. MIRM shares are trading -0.81% year to date (YTD), with the 12-month market performance up to 29.79% higher. It has a 12-month low price of $20.81 and touched a high of $35.56 over the same period. MIRM has an average intraday trading volume of 683.65K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.02%, 1.11%, and 3.76% respectively.
Institutional ownership of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares accounts for 93.14% of the company’s 36.96M shares outstanding.
It has a market capitalization of $1.36B and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$4.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.37% over the week and 3.45% over the month.
Analysts forecast that Mirum Pharmaceuticals Inc (MIRM) will achieve an EPS of $Minim, Inc. for the current quarter, $3.87 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Mirum Pharmaceuticals, Inc. while analysts give the company a high EPS estimate of $Monogram Orthopaedics Inc. Comparatively, EPS for the current quarter was $Mirion Technologies, Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 14.93%, and 96.83% over the next financial year.
Looking at the support for the MIRM, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 18, 2023, with the firm’s price target at $60-$58.
